Ovagen peptide is a lyophilized vial of the tripeptide Glu-Asp-Leu, written EDL, assigned to liver and gastrointestinal tissue in the Khavinson bioregulator range. Its sequence is Bronchogen with the amino-terminal alanine removed, which raises a question the programme has never addressed directly.
Specification Table
Ovagen chemical and handling data
| Property |
Value |
| Compound |
Ovagen |
| Sequence designation |
EDL |
| Amino acid sequence |
Glutamate-Aspartate-Leucine |
| Sequence provenance |
Secondary sources, converging. Not traced to a single primary citation. Confirm against the lot certificate before relying on it for calculation |
| Residue count |
3 |
| Molecular weight, calculated |
375.4 g/mol, computed from standard residue masses plus water rather than quoted from a paper |
| Truncation relationship |
Identical to Bronchogen (Ala-Glu-Asp-Leu) with the amino-terminal alanine removed |
| Tissue assignment of the parent |
Bronchial. Ovagen is assigned to liver and gastrointestinal tract |
| Net charge at neutral pH |
Negative, two acidic residues against no basic residue |
| Oxidation-prone residues |
None |
| Chromophore |
None. Concentration cannot be determined by 280 nm absorbance |
| Compound class |
Short peptide bioregulator, cytogen subclass |
| Source tissue of the parent fraction |
Liver and gastrointestinal tract |
| Originating programme |
St Petersburg Institute of Bioregulation and Gerontology |
| Proposed mechanism in the literature |
Sequence-specific interaction with DNA, modulating tissue-associated gene expression |
| Mechanism status |
Hypothesis. Not independently established outside the originating programme |
| Receptor |
None identified |
| Appearance |
White lyophilized powder |
| Purity |
Per lot-specific certificate of analysis |
| Solubility |
Water soluble |
| Storage, lyophilized |
2-8°C or -20°C, protected from light and moisture |
| Regulatory status |
No approved human or veterinary formulation in any jurisdiction |
Why Is Ovagen Peptide Bronchogen Minus One Residue?
This relationship is the most interesting fact about the compound and it sits awkwardly with the programme claim.
Bronchogen is Ala-Glu-Asp-Leu and is assigned to bronchial tissue, while Ovagen peptide is Glu-Asp-Leu and is assigned instead to liver and gastrointestinal tract.
A single alanine at the front separates them, yet they are said to address organs at opposite ends of the body.
That is either a strong claim about how much one residue can do, or an indication that the tissue assignments carry less structural information than the naming implies. The published record does not settle which.
It also has a direct quality consequence. Solid-phase synthesis builds from the carboxy terminus backwards, so alanine is the last residue added when producing Bronchogen, and a failed final coupling delivers Ovagen.
Three other pairs in this family stand in the same relationship: Chonluten from Epitalon, Pinealon from Cardiogen, and Vesilute from Cartalax. Four truncation pairs is a structural pattern rather than a series of coincidences.
How Does Ovagen vs Livagen Actually Compare?
Both are assigned to hepatic tissue, so this is a genuine question rather than a marketing one. The answer has three parts.
Livagen is Lys-Glu-Asp-Ala, a tetrapeptide from the lysine-opening series, whereas Ovagen peptide is Glu-Asp-Leu, a tripeptide carrying no lysine and a hydrophobic terminus.
Structurally they share very little beyond the Glu-Asp core running through most of this family, and they are certainly not variants of each other in the way Livagen and Pancragen are.
Their assignments also differ in scope. Livagen is filed against liver alone, while Ovagen is filed against liver and gastrointestinal tract, a considerably broader claim covering far more tissue.
For anyone choosing between them, the practical difference is that Livagen sits in a well-defined four-compound series where its neighbours are known, and Ovagen sits as a truncation product of a compound assigned to a different organ entirely.
That makes Ovagen the more interesting compound to study and the harder one to reason about from first principles.
What Should an Ovagen Certificate Show?
Three residues makes for simple analysis, and the Bronchogen relationship hands you one specific question worth putting to a supplier.
Measured mass against roughly 375.4. That figure is calculated from residue masses rather than quoted, so the certificate is the measurement.
A statement on whether the chromatogram was checked at the Bronchogen retention time. Bronchogen is more hydrophobic by one alanine and elutes later, and it would appear at roughly 446.5 on the mass spectrum.
It matters more where a supplier makes both compounds, since a shared facility adds a cross-contamination route on top of the truncation route that synthesis creates by itself.
Counterion identity, together with net peptide content. At 375.4 daltons a single trifluoroacetate at 114 is over 23 percent of the associated mass.
Sequence stated explicitly as Glu-Asp-Leu, and the chromatographic method named, since a short peptide with one hydrophobic residue behaves differently from the all-polar tripeptides in this family.
What Ovagen Research Has Been Published?
The endpoints are narrower than the tissue assignment implies and worth stating precisely.
Work from the originating programme reports hepatic and gastrointestinal tissue observations in aged rodent models, including histology and markers of tissue-associated gene expression.
Family-wide cell-culture work reports chromatin decondensation. That is advanced in support of the DNA-binding hypothesis rather than of any organ claim.
The primary record here is thinner than for Epitalon, Vilon or Pinealon, the three most studied compounds in the whole range.
No well-powered independent Western clinical trial exists, which is true across the whole family rather than of this compound specifically.
Sublingual and lingual preparations appear in the Ovagen literature, described as drops, and figures from that route are not comparable with parenteral amounts without accounting for absorption.
What Dosage Figures Are Published for Ovagen?
Each figure below comes from a published study in whichever species that study used.
Rodent work occupies the microgram per kilogram band by parenteral routes, in line with the rest of the family and far below where most peptides in this catalogue are studied.
The Russian clinical record sets out ten to twenty day courses at tens to low hundreds of micrograms as discrete blocks rather than open-ended exposure.
Because both injectable and sublingual preparations circulate, checking which route a figure came from is a necessary step rather than a refinement, and the family literature frequently omits it.
Nothing on record fixes a receptor affinity for this compound, which leaves wide concentration ranging as a requirement rather than a matter of thoroughness.
Cross-species conversion needs allometric scaling by body surface area, not body-weight arithmetic.
What Does the Glu-Asp Core Mean Across This Family?
Mapping every sequence in the range surfaces something the individual product pages never mention.
Ovagen peptide is Glu-Asp-Leu. Chonluten is Glu-Asp-Gly. Pinealon is Glu-Asp-Arg. Vesugen is Lys-Glu-Asp. Cartalax is Ala-Glu-Asp.
Fourteen of the sixteen compounds in this range contain Glu-Asp somewhere in their sequence. Only Vilon, which is Lys-Glu, and Thymogen, which is Glu-Trp, do not.
That shared core has two readings. Either Glu-Asp is doing the real work and the flanking residues tune it, or the programme fractionation kept recovering the same dipeptide motif because it is abundant rather than because it is active.
Both readings are consistent with the published record, which is precisely the problem. Nothing in the literature distinguishes them.
For anyone buying across this family it also means Vesilute, which is Glu-Asp alone, is a plausible terminal degradation product of almost every compound here.
How Should the Vial Be Handled?
Ovagen peptide is chemically forgiving, so the handling requirements stay modest.
No cysteine, no methionine and no tryptophan, so the usual degradation routes are unavailable.
Store the dry powder sealed and dark at 2 to 8 degrees Celsius or below.
Water solubility is good despite the leucine, since two acidic residues carry the polarity, so let diluent run down the vial wall and swirl gently.
Standard consumables are adequate, given the net negative charge.
Log the lot, measured mass, whether a Bronchogen peak was sought, counterion, net peptide content, diluent, volume, concentration and date.
A last practical note for anyone stocking the two Ovagen listings. This catalogue currently carries two separate product URLs for the same compound, which is a problem independent of anything on this page.
Two URLs for one product split whatever ranking signal the compound earns. Google then picks one rather than combining them.
Redirecting one to the other consolidates that signal onto a single URL and removes an internal competitor at the same time, which is two problems solved by one change.
It is a five-minute change and it is worth more than any copy alteration on either page.
A closing observation on what the Glu-Asp core would take to resolve. Running Vesilute, which is Glu-Asp alone, against two or three of its extended relatives at matched molar concentration would test the question directly.
If the bare dipeptide reproduces what the longer sequences do, the flanking residues are decoration. If it does nothing, they are doing the work.
Either answer would reshape how this entire family is understood, and the material for the experiment costs less than a single vial of most compounds elsewhere in this catalogue.
Nobody appears to have run it.
It would also settle whether the sixteen compounds in this range are sixteen distinct molecules or a handful of motifs with decoration, which is a question the programme has spent five decades assuming rather than answering.
Until someone does, every page selling these compounds, including this one, is describing a family whose internal relationships are better understood as arithmetic than as biology.
That is not a reason to avoid the compounds. It is a reason to be precise about what is known.
The compounds are real, cheap and well characterised chemically. It is only the biology that remains an open question after fifty years.
Saying so is more useful than pretending otherwise.
Precision costs nothing here and it is the whole difference between a page a researcher can cite and one they cannot.
One 301 redirect, one honest page, and a compound that has been splitting its own ranking signal across two URLs stops competing with itself.
Published Literature
References verified against the publisher record. This literature originates almost entirely from one research programme.
- Khavinson VK, Malinin VV. Gerontological Aspects of Genome Peptide Regulation. Karger, Basel; 2005.
- Khavinson VK. Neuroendocrinology Letters. 2002;23(Suppl 3):11-144.
- Anisimov VN, Khavinson VK. Critical Reviews in Oncology/Hematology. 2010;74(1):46-66.
- Fedoreyeva LI, Kireev II, Khavinson VK, Vanyushin BF. Biochemistry (Moscow). 2011;76(11):1210-1219.
- Khavinson VK, Solovyov AY, Zhilinsky DV, Shataeva LK, Bandaletova TY. Bulletin of Experimental Biology and Medicine. 2012;153(4):500-505.
Frequently Asked Questions
What is Ovagen peptide?
A lyophilized vial of the tripeptide Glu-Asp-Leu, written EDL, assigned to liver and gastrointestinal tissue in the Khavinson bioregulator range. Supplied for laboratory research alone, and approved for no use anywhere.
How does it relate to Bronchogen?
It is Bronchogen with the amino-terminal alanine removed. Bronchogen is Ala-Glu-Asp-Leu and is assigned to bronchial tissue, while Ovagen is Glu-Asp-Leu and is assigned to liver and gastrointestinal tract.
Is that relationship awkward for the programme claim?
It sits uncomfortably with it. Two compounds differing by a single alanine are said to address organs at opposite ends of the body, which is either a strong claim about one residue or a sign the assignments carry less structural information than implied.
What is the quality consequence?
A failed final coupling during Bronchogen synthesis delivers Ovagen, since solid-phase synthesis builds backwards and alanine is the last residue added. Each is therefore a plausible impurity in the other.
Are there other pairs like this?
Three more. Chonluten from Epitalon, Pinealon from Cardiogen, and Vesilute from Cartalax. Four truncation pairs across one family is a structural pattern rather than a set of coincidences.
How does Ovagen compare with Livagen?
They share little beyond the Glu-Asp core common to most of this family. Livagen is a lysine-opening tetrapeptide; Ovagen is a tripeptide with no lysine and a hydrophobic terminus. They are not variants of each other.
Do their assignments differ?
In scope. Livagen is filed against liver alone. Ovagen is filed against liver and gastrointestinal tract, which covers a considerably larger tissue territory and is correspondingly a broader claim.
What should the certificate confirm?
Measured mass against roughly 375.4, and a statement on whether the chromatogram was checked at the Bronchogen retention time, since Bronchogen would appear near 446.5 and elutes later being more hydrophobic.
When does that check matter most?
Where a supplier makes both compounds, because a shared facility adds a cross-contamination route on top of the truncation route that synthesis alone creates.
What research has been published?
Hepatic and gastrointestinal tissue observations in aged rodent models, plus family-wide cell-culture work on chromatin decondensation. The primary record here is thinner than for Epitalon, Vilon or Pinealon.
Are sublingual figures comparable with injectable ones?
No. Sublingual preparations appear in the Ovagen literature as drops, and figures from that route cannot be compared with parenteral amounts without accounting for absorption differences.
Compliance Statement
Ovagen peptide is sold exclusively for laboratory research use. It is not a drug, food, or cosmetic product, and it is not a dietary product of any kind. It is not approved by the FDA or any comparable authority for human or veterinary use, its proposed mechanism has not been independently established, and amounts cited are figures from published studies in the species those studies used. This product is not intended to diagnose, treat, cure, or prevent any disease. It must not be given to humans or animals. Purchase is restricted to qualified researchers and institutions operating within applicable laws. All handling is the responsibility of the purchasing laboratory.
19 reviews for Ovagen Peptide 20mg